Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 4/2001

01-07-2001 | Originales Breves

Deletion of the N-acetyltransferase-2 (NAT2) gene is an early-common event in the squamous cell carcinoma of the head and neck

Authors: Eliecer Coto García, Juan Pablo Rodrigo Tapia, Victoria Álvarez Martínez, María Victoria González Meana, Carlos Suárez Nieto

Published in: Clinical and Translational Oncology | Issue 4/2001

Login to get access
Metadata
Title
Deletion of the N-acetyltransferase-2 (NAT2) gene is an early-common event in the squamous cell carcinoma of the head and neck
Authors
Eliecer Coto García
Juan Pablo Rodrigo Tapia
Victoria Álvarez Martínez
María Victoria González Meana
Carlos Suárez Nieto
Publication date
01-07-2001
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 4/2001
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/BF02712693

Other articles of this Issue 4/2001

Clinical and Translational Oncology 4/2001 Go to the issue

Sección Docente

DNA repair

Originales

Astrocitomas cerebrales. Factores pronósticos en una serie de pacientes tratados en México

Legacy

Información

Originales

Sacropelvic resection and intraoperative radiation therapy: feasibility, technical description and early clinical results

Notas Clínicas

Sarcoma de Kaposi en un paciente con linfoma T periférico

Originales

Vacunación idiotípica en linfomas B de bajo grado: una nueva terapia antitumoral
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits